Thomas Jefferson University

Jefferson Digital Commons
Alpers Day Resident Research Symposium

Department of Neurology

5-19-2022

2022 Alpers Day Neurology Residency Abstracts
Neurology Residency, Thomas Jefferson Univerisity

Follow this and additional works at: https://jdc.jefferson.edu/alpers_resident_research_symposium

Let us know how access to this document benefits you
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital
Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is
a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections
from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested
readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been
accepted for inclusion in Alpers Day Resident Research Symposium by an authorized administrator of the
Jefferson Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.

THE DEPARTMENT OF NEUROLOGY
presents

THE FIRST ANNUAL

ALPERS DAY
Resident Research
Symposium
Thursday, May 19th, 2022

SUBMITTED ABSTRACTS
PGY4 CAPSTONE RESEARCH PROJECTS
Metabolomics in Epilepsy
Braslavsky M, Basovic L, Rehman M, Gal J, Kaushal G, Bhushan A, Nei M..................................................5

Exploration of Antipsychotic Prescribing Practices Among Movement Disorders Subspecialists
for Patients with Parkinson’s Disease Dementia and Dementia with Lewy Bodies
Burda KV, Selbst D, Margolis J, Heiry M...............................................................................................................6

Metabolomic analysis of extracellular vesicles from in Multiple Sclerosis
Chuang TY, Kenkare A, Casella G, Sheehan L, Rostami AM............................................................................ 7

The relationship between wearing-off between medication doses in patients with
Multiple Sclerosis (MS) on disease modifying therapies (DMTs) and body mass index (BMI)
Gruder O, Devlin K, Leist T..................................................................................................................................... 8

SETscore to Determine Prolonged Mechanical Ventilation Times and NICU-LOS for
All NICU Patients with Brain Injuries
Lee E, Selbst D, Leist T, Shah S.............................................................................................................................. 9

Effectiveness of in-patient implantable Heart Monitor in capturing afib in
cryptogenic stroke patients
Lee H......................................................................................................................................................................... 10

Hypertonic saline use in post cardiac arrest patients for treatment of cerebral edema
Maguire L, Dolla A, Shah S, Thomas T. .............................................................................................................. 11

Neurostimulant Medication Application in Acute Patients in the Neurocritical Care Unit
Kananeh M, Birkenstock L, Navarathna K, Sharma K, Shah S, Vibbert M................................................... 12

A Review of Effect of Ticagrelor on Platelet Inhibition in Clopidogrel Non-responders
Undergoing Neuroendovascular Procedure
Patel P, Herial N, Gooch M, Tjoumakaris S, Jabbour P.................................................................................. 13

Assessment of Outcomes for Acute Stroke Patients Boarding in Emergency Department
Porreca L.................................................................................................................................................................. 14

A Review of Neurologic Complications from Cryptococcal Meningoencephalitis in the
Previously Immunocompetent Patient after COVID-19 Infection
Pynes M, Azuma R, and Thaete L....................................................................................................................... 15

SUBMITTED ABSTRACTS
QUALITY IMPROVEMENT COMMITTEES’ PROJECTS
Efficacy of the Implementation of Brain Herniation Codes at a Tertiary Medical Center
Lee E, Maguire L, Pynes M, Curran C, Hsu R, Buslov A, Lee H, Navarathna K,
Vibbert M, Shah S........................................................................................................................................................ 16

Increasing Resident Fundoscopic Examination Documentation and Knowledge
with Educational Session
Gruder O, Azuma R, Liao L, Fox N, Burke R, Yang QZ, Ahmed E, Ambrose T,
Berk M, McCall J. .................................................................................................................................................. 17

Improving Resident Continuity Clinic Efficiency
Wang V, Burda K, Super M, Chuang TY, Braslavksy M, Volski A, Yi J, Wong E,
Heiry M, Miskin D, Martinez N, Vu AT................................................................................................................ 18

Risk Factor Evaluation for Aspiration Pneumonia at a Comprehensive Stroke Center
Silver M, Patel P, Graese P, Gal J, Newman J, Porreca L, Elias B, Tzeng D,
D’Ambrosio R, Dharia R. ...................................................................................................................................... 19

OTHER SUBMITTED RESIDENT PROJECTS
Factors Associated with Morbidity and Mortality in Acute Ischemic Stroke in Patients
with SARS-CoV-2 Infection
Chuang TY, Magee R, Li M, Khalife J, Bell R, Miller E.......................................................................................... 20

Effectiveness, Safety, and Tolerability of Repetitive IV Dihydroergotamine in the
Treatment of Refractory Chronic Migraine – A Retrospective Review
Wang V, Kosman J, Yuan H, Hopkins M, Lauritsen C, Silberstein S ........................................................... 21

Metabolomics in Epilepsy
Braslavsky M, Basovic L, Rehman M, Gal J, Kaushal G, Bhushan A, Nei M

INTRODUCTION/ PURPOSE

differences analyzed via paired t-tests. Group data
will be compared via t-tests evaluating peak area for
identified metabolites for statistically significant
changes (p<0.05).

Excessive hypersynchronous activation in the
cortex causes seizures, though precise biochemical
mechanisms underlying seizure initiation,
propagation and termination are unknown.
Metabolomics, the study of small molecule
chemicals involved in metabolic processes, can
reveal novel and unexpected biomarkers in
epilepsy. This pilot study looks to characterize
metabolomic changes in focal epilepsy patients
baselin e an d p os tict ally, to un ders t an d
corresponding changes in metabolism.

CONCLUSION
Differences in metabolomics profiles specific to
the post-ictal period and epilepsy may eventually
help diagnostically. They could differentiate
epileptic from non-epileptic seizures, avoiding
unnecessary medications. In low-resource
settings without EEG, a standardized blood test
could provide an alternative. This could aide in
assessing treatment response. Further like studies
could also correlate with specific epilepsy types
and elucidate drug targets.

HYPOTHESIS
There are significant alterations in specific
compounds after seizure, identified by targeted and
untargeted metabolomics, including lactate, glyceraldehyde, trans-13-octadecenoic acid, glycine, and
citrate, during the post-ictal period, compared with
baseline, in patients with focal epilepsy.
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We expect to recruit 10 patients with refractory
focal epilepsy admitted to the epilepsy monitoring
unit. Nursing staff was trained on sample collection
and storage. Clinical neurology providers were
trained on informed consent, recruitment and
sample distribution. Baseline (12 hours after
seizure), post-exercise and post-ictal (each within
10 minutes) plasma samples are collected for
metabolomics analysis. Pharmaceutical sciences
team will analyze samples.

3. Heischmann S, Quinn K, Cruickshank-Quinn C, Liang L, Reisdorph R,
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RESULTS/ PROGRESS/ DATA ANALYSIS
Despite initial delays relating to the COVID-19
pandemic and interdisciplinary coordination, staff
training, recruitment and sample collection has now
begun (Appendix I). Once equipment is installed,
standardization and sample analysis will start. The
amount (peak area) of each metabolite at baseline
will be compared with post-ictal profile and

8. Patel, Manisha. “A Metabolic Paradigm for Epilepsy.” Epilepsy currents vol. 18,5
(2018): 318-322. doi:10.5698/1535-7597.18.5.318
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a shared serum metabolic characteristic among three types of epileptic
seizures. Epilepsy Research 2016: 126: 83-89
10. Wei S, Liu L, Zhang J, Bowers J, Gowda GAN, Seeger H, Fehm T, Neubauer HJ,
Vogel U, Clare SE, Raftery D. Metabolomics approach for predicting response
to neoadjuvant chemotherapy for breast cancer. Mol Oncol. 2013; 7: 297–307.
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Exploration of Antipsychotic Prescribing Practices
Among Movement Disorders Subspecialists for
Patients with Parkinson’s Disease Dementia and
Dementia with Lewy Bodies
Burda KV, Selbst D, Margolis J, Heiry M

BACKGROUND/PURPOSE
Psychosis in Parkinson’s Disease Dementia (PDD) and Dementia with Lewy Bodies (DLB) contributes to
decreased quality of life and increased healthcare resource utilization. Many antipsychotic drugs (APDs) can
worsen parkinsonian symptoms. Pimavanserin has been associated with superior outcomes and fewer
adverse effects compared with other APDs. However, the prevalence of its utilization has not been
well-studied. This study explored APD prescribing practices with a focus on Pimavanserin in the PDD and
DLB population.

METHODS
Physician members of the International Parkinson and Movement Disorder Society (MDS) were surveyed
regarding management of psychosis in PDD and DLB. Statistical analysis was performed using Excel and
SPSS.

RESULTS
496 physicians completed the survey. Factors cited as most significant when initiating APDs included
“severity of psychosis” (79.2%) and “side effect profile” (49.2%). Quetiapine was the most prescribed APD
for both PDD (54.6%) and DLB (44.2%). Of the 149 respondents who had ever prescribed Pimavanserin,
65.8% reported using it only for escalation when other treatments failed. Commonly cited limitations in
prescribing Pimavanserin included cost (80.4%) and availability (51.9%).
Pimavanserin use was higher among U.S.-based respondents compared to the international community
[PDD OR = 4.52 (CI 1.68-12.15); DLB OR = 4.19 (CI 1.79-9.82)]. Among all prescribers of Pimavanserin,
those from the U.S. and those predominantly in the academic setting were significantly less likely to use
Pimavanserin first-line vs. after trialing other medications [U.S.-vs-Others OR=0.37 (CI 0.16-0.86);
Academic-vs-Community OR=0.32 (CI 0.14-0.69)].

CONCLUSION
Quetiapine remains the most popular APD for both PDD and DLB. Pimavanserin use is significantly more
common among U.S. respondents compared to the international community; however, U.S. respondents
are more likely to use it as an escalation therapy rather than a first-line medication. In the U.S., use of
Pimavanserin as a first-line APD is significantly more common among providers in the community setting
vs. the academic setting.
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Metabolomic analysis of extracellular vesicles
in Multiple Sclerosis
Chuang TY, Kenkare A, Casella G, Sheehan L, Rostami AM

BACKGROUND/PURPOSE
Multiple Sclerosis (MS) is a progressive neurological disease which affects over 2.8 million people worldwide.
MS-specific biomarkers predictive of disease exacerbation and outcome remain elusive. Extracellular vesicles
(EVs) are potential sources of biomarkers, as they are a method of cell-cell communication and cargo
delivery. There is growing literature regarding the role of EVs in multiple disease states, including MS. In this
study, we elucidate the metabolomic profile of extracellular vesicles in the cerebrospinal fluid (CSF) and
serum samples of MS patients versus controls.

METHODS
CSF and serum specimens were collected from MS (n=7) and control (n=6) patients. The extracellular
vesicles were then isolated via filtration and ultracentrifugation using established methods. Samples were
analyzed via Liquid Chromatography-Mass Spectrometry (LC-MS) at The Wistar Institute. Metabolomic
data were filtered and normalized using Metaboanalyst 5.0.

RESULTS
We found that CSF metabolites differ between MS and control patients, specifically those of collagen
component 4-hydroxyproline (p-value = 0.007) and linoleic acid derivative 9 Oxo-ODE (p-value = 0.007).
In CSF EVs, 4-hydroxyproline was significantly increased (p-value = 0.02), while taurine was significantly
decreased (p-value = 0.04). Serum metabolites involved in glycerolipid, glycerophospholipid, and nicotinate
and nicotinamide metabolism are increased in MS patients. Serum EVs also contain significantly increased
metabolites involved in purine and glycerolipid pathways in MS patients.

CONCLUSIONS
EVs are known to cross the blood-brain barrier and are potential biomarkers for disease state prognosis.
Our analysis demonstrated that EVs in the CSF of MS patients have different metabolomic profiles
compared to serum EVs. We also established that the EVs in MS patients have different metabolomics
compared to control. Further studies are ongoing to dissect the details of these metabolic pathways in
MS and their significance in immunopathogenesis.

7

The relationship between wearing-off between
medication doses in patients with Multiple
Sclerosis (MS) on disease modifying therapies
(DMTs) and body mass index (BMI)
Gruder O, Devlin K, Leist T

BACKGROUND
Despite advancements in DMTs used for MS, there is only one standard dosing for DMTs. Some patients a
wearing-off effect or worsening MS baseline symptoms shortly before their next infusion is due. We
hypothesized that patients with higher BMI’s have a greater frequency of wearing-off in between their
infusion intervals and may need alternative dosing regimens.

OBJECTIVES
The aim of this study was to perform an institutional survey-based review to determine if the phenomenon
of wearing off DMTs is related to BMI. Additionally, we will compare wearing off to additional demographics
including age, recent weight loss or weight gain, type and duration of infusions. The purpose of the study
is to utilize these demographics to determine if alternative dosing regimens for DMTs for certain patient
populations are suggested.

METHODS
Patients with RRMS and PPMS who previously underwent at least one infusion of a DMT were included
in the study. Prior to or during each infusion, patients completed the Multiple Sclerosis Impact Scale
(MSIS-29), The Center for Disease Control and Prevention Health-Related Quality-of-Life 14-Item Measure
(CDC HRQoL-14) and a general survey about wearing-off devised for this study. Height and weight were
obtained on the day of survey completion to allow for accurate BMI calculation.

RESULTS
67 patients agreed to participate during the 3-month time period. The infusions received were rituximab,
ocrelizumab and natalizumab. 80.6% of all patients reported at least one symptom of wearing off prior
to their next infusion dose. There was no statistically significant relationship between wearing off and BMI,
though there was with the MSIS Physical Impact Score. Each increased point on the MSIS scale was
associated with an 8% increased odds of wearing off.

CONCLUSIONS
80.6% of MS patients surveyed reported wearing off prior to their next infusion which appeared to only
be related to MSIS scale. This raises the question if these patients are reporting greater impact because
they are wearing off or if they may have had a more severe form of the disease. In the future, we should
evaluate the relationship between wearing off in certain MS subtypes, duration of infusions, and MRI
lesion burden. Understanding proper dosing regimens may help us better serve our patients and improve
their quality of life.
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SETscore to Determine Prolonged Mechanical
Ventilation Times and NICU-LOS for All NICU
Patients with Brain Injuries
Lee E, Selbst D, Leist T, Shah S

Patients that are mechanically ventilated (MV) in the NICU differ from other ICU patients due to the nature
of their injuries involving the brain. One study created the SETscore to predict which non-traumatic
cerebrovascular patients would have prolonged MV times and thus promote early tracheostomies. Our
study examines if the SETscore can be applied to all NICU patients with other brain injuries (non-CVA)
besides cerebrovascular ones.
We retrospectively reviewed patients requiring MV within 48-hours of admission in the NICU from
2019-2022. We excluded patients intubated for a procedure, had withdrawal of care without an extubation
attempt, or expired within 48-hours of admission. We compared the average MV time and NICU-LOS for
patients using unpaired t-tests to see if SETscores would correctly predict those variables for our cohort.
We also compared averages for non-CVA patients with CVA patients to see if it similarly predicted MV
times and NICU-LOS.
CVA patients with SETscores > 10 did have longer average MV times (10.10+1.80) than CVA patients with
SETscores < 10 (1.50+0.50), (p=0.067). Non-CVA patients with SETscores > 10 (13+6.30) had similar MV
times to non-CVA patients with SETscores < 10 (12.3+1.82), (p=0.89). There was no significant difference
in average NICU-LOS in both CVA (p=0.64) and non-CVA groups (p=0.43). When comparing CVA with
non-CVA patients with SETscores > 10, the average MV times were similar (p=0.58). For patients with
SETscores < 10, MV times between CVA and non-CVA patients were not significantly different (p=0.074).
Currently, our data doesn’t show a significant difference in all groups based on their SETscores and
injuries. This may be due to our cohort being from a tertiary care center with generally sicker patients.
Our study also had an n=36. With the addition of more data, SETscores could predict prolonged MV times
and NICU-LOS. This would encourage early tracheostomies, improving clinical outcomes, overall hospital
LOS, and costs.
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Effectiveness of in-patient implantable
Heart Monitor in capturing afib in cryptogenic
stroke patients
Lee H

INTRODUCTION
Atrial fibrillation (AF) is a recognized risk factor of ischemic stroke and AF-related stroke is twice more likely
to prove fatal. Long-term cardiac rhythm monitoring has greater diagnostic yield compared to conventional
monitoring in detecting AF. Utility of implantable loop recorder (ILR) in detecting AF was established not
only in patients with cryptogenic stroke but more recently in strokes due large artery atherosclerosis and
small vessel disease Stroke AF trial. We reviewed 3 years of data from patients who had both inpatient and
outpatient ILR placement at a comprehensive stroke center.

METHODS
A review of prospectively collected registry of ILR implantations performed at a Comprehensive stroke
center was conducted. Data from 2017–2019 of in-patient and out-patient implantation was analyzed.
Eligible patients identified by vascular neurology (VN) underwent in-patient implantation primarily by
interventional neurology (IN) and as out-patient by electrophysiology Cardiology. In-patient implant and
programming were done on the day of discharge. Continuous monitoring was followed by EP Cardiology.
AF detection was urgently communicated by EP Cardiology and anticoagulation initiated by VN. Patients
lost to follow up or lacking information in medical records were excluded from analysis.

RESULTS
Total of 428 ILR implantations were performed over a period of 3 years (1/2017 - 12/2019) with majority
implants as in-patient prior to discharge 290 (67.8%) and out-patient 78 (32.2%). Inpatient ILR placement
was noted to be 75% in 2017, 78% in 2018 and 80% in 2019. 57.2% of in-patient ILRs were placed by IN
and 42.8% by EP. Average time to in-patient ILR was 4.1 days with 77% within 5, 18.5% within 10, and <5%
within 11 or more days post-stroke. Average time to out-patient ILR placement was 57 days with only
16% within 15, 29% within 30 day and 53% in more than 30 days from stroke. Over the course of 2 years
of monitoring, AFib was detected in 33% with false detection in 1.5% (19.6% in 2017, 26% in 2018 and
36.5% in 2019).

CONCLUSIONS
A multispecialty collaborative care pathway to increase implantation rate in eligible patients is
recommended. In-patient implantation allows establishing continuity of care, patient retention, prevents
lost to follow-up, avoids delay in monitoring, and importantly decreases the risk of stroke recurrence by
early initiation of anticoagulation.
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Hypertonic saline use in post cardiac arrest patients
for treatment of cerebral edema
Maguire L, Dolla A, Shah S, Thomas T

BACKGROUND
Hypoxic brain injury in cardiac arrest patients is a leading cause of mortality and long-term disability in its
survivors. There are multiple mechanisms for secondary injury to the brain leading to cell death including
reperfusion injury, microcirculatory dysfunction, and vasogenic or cytotoxic edema. The use of hypertonic
saline (HTS) has been previously shown to reduce secondary injury in animal models by reducing
inflammatory cascades, improving microcirculatory flow, and reducing cerebral edema. Thus far, evaluation
of hypertonic saline use in humans post cardiac arrest has not been fully evaluated. We hypothesize that
cardiac arrest patients receiving HTS do not have worsened clinical outcomes or increased mortality due
to complications secondary to HTS therapy.

METHODS
This study is a retrospective feasibility study of adult cardiac arrest patients at TJUH who received HTS for
reduction of cerebral edema and neuronal injury during their hospital course. Data was compared with
age and gender matched cardiac arrest control patients. Primary and secondary endpoints include CPC
score at discharge and in-hospital mortality, pulmonary edema and acute kidney injury (AKI). Statistical
analysis was performed using Graphpad prism v9.

RESULTS
Retrospective chart review was performed on 17 cardiac arrest patients receiving HTS and 10 controls
(Age 44.76±3.25 vs 48.50±4.67 respectively, p=0.5). Initial CT head revealed cerebral edema in 70.59%
HTS and 20% control patients (p=0.018). HTS patients had higher numbers of AKI on presentation
(p=0.049), however no difference was found in CPC scores at discharge and in-hospital mortality (p>0.05)
between groups.

CONCLUSION
In conclusion, there were no significant changes in CPC score or in-hospital mortality for patients treated
with HTS verses those who were not. Future studies should be performed to address whether these
outcome measures can be improved by early initiation of HTS prior to development of cerebral edema on
CT head.
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Neurostimulant Medication Application in
Acute Patients in the Neurocritical Care Unit
Kananeh M, Birkenstock L, Navarathna K, Sharma K, Shah S, Vibbert M

INTRODUCTION
Many patients admitted to the neurocritical unit (NCCU) are in a non-responsive state. Numerous reports
have been published on the use of neurostimulant medications (NSMs) to help improve consciousness in
brain injured patients. Most of these reports have been on chronic vegetative or minimally conscious state
patients. There is limited prospective data on the use of NSMs in the acute setting.

METHODS
We prospectively collected data on patients admitted to Thomas Jefferson University Hospital’s NCCU
from 2/2019 to 3/2020. We collected demographic data, GCS on day one of starting NSMs and three
days after, medications, infections and creatinine. Modafinil or Adderall were started on stabilized patients
with persistent GCS ≤ 9. A positive response was defined as an improvement in GCS by 2 points within
3 days.

RESULTS
73 patients received NSMs (17 Adderall and 58 Modafinil). Patients admitted with stroke were unlikely to
benefit from NSMs (p < 0.001). There was no significant relationship between NSMs and improvement
in GCS in patients admitted with seizures, anoxic brain injury, brain trauma, tumors or CNS infections.
There was no significant relationship between starting NSMs and improvement in GCS in patients with
encephalopathy, interictal brain activity (GPDs or LPDs), systemic infections or on antibiotics or AEDs.
Adderall was discontinued in 5 patients (4 tachycardia, 1 hypertension). Modafinil was stopped in
3 patients (2 seizures and 1 tachycardia).

CONCLUSION
Using NSMs for three days was insufficient to improve GCS in our patients. Longer durations of NSM use
may be provide benefit but further research is needed.
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A Review of Effect of Ticagrelor on Platelet Inhibition
in Clopidogrel Non-responders Undergoing
Neuroendovascular Procedure
Patel P, Herial N, Gooch M, Tjoumakaris S, Jabbour P

INTRODUCTION
Neuroendovascular procedures are routine in treatment of aneurysms, arterial stenosis, and ischemic stroke.
Patients are treated with antiplatelets prior to procedure to prevent thrombotic complications. However,
some patients may still experience post procedural thrombotic or hemorrhagic complications which may
be related to platelet inhibition.

METHOD
A retrospective review of patients who underwent neuroendovascular procedure from 1/2017 to 12/2019
in Jefferson hospital. Patients undergoing elective procedure received DAPT daily. Patients undergoing
emergent procedures received loading doses of Aspirin (650 mg) and Clopidogrel (600 mg). P2Y12 assay
was checked prior to receiving Platelet inhibitor and 6 hours after loading dose. Optimal platelet inhibition
was classified as reduction in P2Y12 assay by at least 60%. Patients with suboptimal platelet inhibition
<60% were given Ticagrelor loading dose (180 mg) and assay was rechecked.

RESULT
Total procedures requiring stents were 687 over period of 3 years. These included aneurysm stenting
239, aneurysm stent-assisted coiling 112, intracranial stent for failed MT 62, carotid artery stent 108.
Suboptimal platelet inhibition was noted in 54% after Clopidogrel. After Ticagrelor, optimal inhibition was
noted in 80% of 282. Thrombotic complications were noted in 7, 6 were noted to have <50% platelet
inhibition. Hemorrhagic complications were noted in 17, amongst them >70% platelet inhibition was
noted in 14 patients.

CONCLUSION
Patients receiving P2Y12 ADP antiplatelet therapy may have suboptimal platelet inhibition leading to
increased thrombotic risk. Patients who have >70% platelet inhibition are at increased risk for hemorrhagic
complications. Better platelet inhibition was achieved with Ticagrelor in Clopidogrel hypo-response
patients. In patients with Clopidogrel hyper-response, dosing was changed to half dose or alternate day
to reduce hemorrhagic complications. As the use of endovascular therapies requiring DAPT becomes
more established, there is an increasing need to develop titration protocols that minimize the risk of
thrombotic and hemorrhagic events based on platelet inhibition.
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Assessment of Outcomes for Acute Stroke Patients
Boarding in Emergency Department
Porreca L

The management of patients with strokes or transient ischemic attacks during the acute phase requires
vigilant, time-sensitive care. An emphasis on efficient disposition to the appropriate inpatient services for
acute stroke patients can avoid crucial delays in this care and subsequent worse clinical outcomes. The
Jefferson Neurology Acute Stroke Unit (ASU) is historically a high-volume service, leaving ample chance for
such adverse results due to the not-infrequent scenario wherein patients admitted to the ASU must spend
time boarding in the Emergency Department (ED) awaiting transfer to their room. Previous research has
shown that the boarding of critically ill patients is associated with substandard results of hospitalization, that
there is a dose-response increase in the incidence of pneumonia per day of delay in dysphagia assessment
in acute stroke, and that patients receiving standard of care treatment of stroke with respect to earlier
administration of dual antiplatelet therapy in patients with low NIH stroke score have better outcomes. We
analyze data from patients admitted to the ASU who spent extended periods of time boarding in the ED
prior to transfer to the ASU to assess for issues that could affect patient safety and outcomes and to gauge
their frequency. While lengthy delay in the administration of antiplatelet agents was noted, overall delays in
completion of aspects of workup including diagnostic testing and evaluations by rehabilitation services
were less than anticipated. Our findings indicate that while increased time spent awaiting transfer can lead
to adverse issues, the length of time boarding has not yielded a frequent number of delays in care.
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A Review of Neurologic Complications from
Cryptococcal Meningoencephalitis in the
Previously Immunocompetent Patient after
COVID-19 Infection
Pynes M, Azuma R, and Thaete L

Cryptococcus neoformans is a fungus that spreads to humans via aerosolized spores from exposure to
bat guaiac, decaying wood, or disturbed soil. Once a fungal spore is inhaled, it may spread to the
bloodstream. Then, it is capable of hematogenous spread to the brain leading to cryptococcal meningitis
in some patients. Cryptococcal meningitis is an infection of the central nervous system that is associated
with high morbidity and mortality. CNS infection with cryptococcus neoformans are reported most often
in immunocompromised hosts. Globally, HIV/AIDs infection is the most common predisposing factor for
the development of cryptococcal meningoencephalitis. Despite the preponderance for cryptococcus
neoformans to preferentially infect immunocompromised hosts, many cases of infection have been
reported recently in immunocompetent individuals.
The COVID-19 pandemic has been associated with increased rates of some systemic mycoses. Proposed
etiologies for this connection include common associations with severe COVID-19 infection such as
hypoxemia, steroids use, mechanical ventilation, and low CD4 count. Systemic fungal infections reported
to occur simultaneously with severe COVID-19 infection include aspergillus, candida species, cryptococcus
neoformans, and mucorales most commonly (Amin 2021). Of the fungal infections with positive
cryptococcal isolates, CNS-infiltrative disease was rare. Anecdotally, more cases have been seen than
have been reported. This paper also aims to introduce the case of a previously immunocompetent
middle-aged man who developed COVID-19 which was treated with dexamethasone and remdesivir. His
COVID-19 disease course was moderate without ventilatory requirement. However, several months later,
he developed recurrent scattered cerebral infarcts and ICP crises, at which time he was found to have
cryptococcal neoformans meningoencephalitis. This patient’s case will seek to demonstrate the
importance of early detection of cryptococcal meningitis/meningoencephalitis to reduce the morbidity
and mortality associated with the condition.
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Efficacy of the Implementation of Brain Herniation
Codes at a Tertiary Medical Center
Lee E, Maguire L, Pynes M, Curran C, Hsu R, Buslov A, Lee H, Navarathna K, Vibbert M, Shah S

BACKGROUND/PURPOSE
Brain herniation is a life-threatening event that occurs when compensatory mechanisms are overcome by
increasing intracranial pressure. We implemented a brain herniation code (BHC) emergency alert protocol
at our institution to improve the time to intervention for these patients. Our purpose is to study the timing
to intervention and clinical outcomes of BHC patients before and after teaching sessions with medical staff.
We hypothesize that the implementation of BHC with focused clinical staff education at TJUH will improve
efficiency of clinical care for the herniating patient as well as clinical outcomes.

METHODS
We retrospectively evaluated BHC patient charts at TJUH between 2019 to 2021. We then provided
educational sessions to house staff with a 10 question pre and post lecture evaluation. Finally, we analyzed
data from BHC occurring after our educational sessions to compare ‘time to intervention’ and ‘clinical
outcome’ of BHC patients. Statistical analysis was performed using Graphpad Prism v9. Pre and post
survey results were compared using paired analysis corrected for multiple comparisons.

RESULTS
Preliminary data found six BHC patients. The average time to obtaining CTH was 39.8 minutes and the
average time to administering hyperosmolar therapy was 56.6 minutes. Most codes were called for
changes in pupillary exam. Regarding our educational intervention, we found a statistically significant
difference in pre and post test scores (n=20, p<0.001) following our teaching session. Providers scored
significantly better on 3 questions directed at recognizing impending herniation and 1 question about
brain herniation protocol (p<0.05, n=20).

CONCLUSION
We found focused teaching sessions had a significant impact on APPs and residents’ comfort level at
recognizing brain herniation, as well as general knowledge of the topic. We believe this will lead to
increased recognition and initiation of BHC and therefore improved time to intervention and clinical
outcomes for our patients.
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Increasing Resident Funduscopic Examination
Documentation and Knowledge with
Educational Session
Gruder O, Azuma R, Liao L, Fox N, Burke R, Yang QZ, Ahmed E, Ambrose T, Berk M, McCall J

BACKGROUND
A full neurological history and physical classically involves a fundoscopic exam. However, it has been
observed that this portion of the examination is rarely performed and documented in medical records on
patients admitted to a neurology service at Thomas Jefferson University Hospital. Fundoscopic examination
is also listed in Neurology Residency Core curriculum and is an ACGME milestone.
We hypothesized that lack of fundoscopic examination may be due to inexperience and discomfort
with fundoscopic exams which motivated our project.

METHODS
We provided one hour of teaching and practicing fundoscopic examinations during resident conference.
We reviewed documentation rates of fundoscopic examinations in the month prior to intervention (99
charts) of patients admitted prior to our intervention and compared them to the month following
intervention (141 charts). Additionally, we surveyed residents with a quiz pre and post education to
objectively measure learning from our teaching session.

RESULTS
Fundoscopic exam documentation increased by 300% post education session (7% to 21%). No significant
difference in documentation rates 8% vs 6%) was found for history and physicals written by non-neurology
residents (providers who did not participate in teaching session). The percent of respondents with correct
answers to the quiz increased post education. 80% of residents reported the session helpful or very
helpful and 20% mildly helpful. Prior to the session, 80% of residents reported feeling very unconfident
or unconfident in performing fundoscopic exams, which decreased to 20% post education session.

CONCLUSION
The education session was successful in improving resident's conceptual knowledge and comfort level
with performing the exam, as well as increasing documentation of fundoscopic exams in neurology
history and physicals. Our results suggest that a fundoscopic education session should be provided for
each cohort of residents. Future considerations include analyzing if the effect of the teaching session
diminishes over time, such that repeat education is needed.
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Improving Resident Continuity Clinic Efficiency
Wang V, Burda K, Super M, Chuang TY, Braslavksy M, Volski A, Yi J, Wong E, Heiry M, Miskin D,
Martinez N, Vu AT

BACKGROUND/PURPOSE
The Department of Neurology Resident Continuity Clinic operates as a general neurology educational
experience giving residents an opportunity to care for their own patients with a wide spectrum of neurologic
conditions. The time spent providing care for patients varies and often extends beyond allotted encounter
time due to time spent evaluating patients, staffing with rotating subspecialty providers, counseling, and use
of interpreter services. The aim of this project was to improve the time to start staffing patients by 20%.

METHODS
A visible queue (white board) was implemented for resident provider staffing with an option to designate
subspecialty attending preferences. Time sheets were completed by resident physicians over four months,
before and after implementation of the intervention. These tracked the time to complete a history and
physical exam, to staff with an attending, to have the attending evaluate the patient, and to wrap up the
visit. Other variables assessed were interpreter use, white board use, visit type (in person, phone,
telemedicine), and residency year. Basic descriptive data were analyzed (Mean, Median, Range, Standard
Deviation, Interquartile Range) through IBM SPSS software.

RESULTS
White board use did not impact time to staffing with attendings (N – 4min vs Y – 5 min) nor total times
spent on direct patient care (N – 39 vs Y – 37 min). Both staffing with a preferred subspecialist and
interpreter use increased the total time spent on a patient visit by about 10 minutes.

CONCLUSION
There is room for improvement with respect to efficiency in the Neurology Resident Continuity Clinic.
We will continue to evaluate our ability to provide neurologic care in a timely manner to improve clinic
flow, patient satisfaction, and patient retention.

18

Risk Factor Evaluation for Aspiration Pneumonia
at a Comprehensive Stroke Center
Silver M, Patel P, Graese P, Gal J, Newman J, Porreca L, Elias B, Tzeng D, D’Ambrosio R, Dharia R

BACKGROUND/PURPOSE
Aspiration pneumonia (AP) is a known complication in acute stroke patients, and is associated with increased
hospital mortality, lengthening hospital stay and post stroke recovery. (Schwarz et al.) In fact in one study
(Heuschmann et al.) highest post stroke in hospital mortality was attributed to AP compared to other
medical complications. At the Jefferson Acute Stroke Unit, the average incidence of AP during hospital stay
is noted to be 2.08%. We aimed to systematically review patients diagnosed with AP with ICD-10 code,
admitted in Stroke Service from October 2017 to October 2021, to evaluate any precursors to developing
Aspiration Pneumonia and factors upon which we could intervene.

METHODS
We performed a retrospective analysis on patients hospitalized in the JHN ASU between October 2017
and July 2021. Patients were included if admission coding included a diagnosis of aspiration pneumonia.
Using a total of 55 patients based on inclusion criteria, we identified 17 different clinical questions to
answer for each patient’s hospitalization. These questions were analyzed for incidence in order to
determine common characteristics and risks in our patients.

RESULTS
In our review, 45 (81.8%) patients were made NPO on admission, amongst these 75% of patients were
noted to have aphasia, dysarthria or dysphagia, 13% had poor mental status, 7% patients were intubated
on admission. SLP consult orders were placed on 35 (63.6%) patients in the first 24 hours of their admission.
SLP consultants also noted to frequently follow-up with these patients, with 46 (83.6%) of these cases
having had multiple SLP evaluations during hospitalization.

CONCLUSION
Patients with any speech deficits, difficulty swallowing, coughing, poor mental status, should be made
NPO on admission until further evaluation of swallowing is conducted. Further research can assist with
criteria to predict high risk groups based on routine care and patient features, along with modifiable risk
factors.
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Factors Associated with Morbidity and Mortality
in Acute Ischemic Stroke in Patients With
SARS-CoV-2 Infection
Chuang TY, Magee R, Li M, Khalife J, Bell R, Miller E

BACKGROUND/PURPOSE
This retrospective, observational cohort study characterizes the factors associated with the development of
acute ischemic stroke in patients with confirmed COVID-19 infection across the Jefferson enterprise. We
compared patient characteristics, laboratory values and clinical outcomes for COVID-19 patients without
stroke (n=1542) to those who were diagnosed with acute ischemic stroke (n=24) at our institution from
March to November of 2020.

METHODS
COVID-19 patients admitted between March 10, 2020 and November 8, 2020 were identified using the
Jefferson EMR with over a total of 42,481 hospital-based patient encounters (inpatient admissions), in
collaboration with Jefferson Health Data Sciences. There was a total of 2,887 patients with COVID-19
diagnosed during an inpatient encounter during this period. Of 154 patients with confirmed COVID-19
and stroke listed by diagnosis codes, acute stroke was confirmed through independent review of MRI
imaging reports. Chart reviewed showed that most stroke ICD-10 codes referred to remote diagnoses. A
total of 24 patients (0.8% of COVID-19 patients) hospitalized with both COVID-19 and acute stroke were
identified. All 24 COVID-19 and stroke patients were admitted through the emergency department.

RESULTS
The majority (70.8%) of patients with COVID-19 and acute stroke were admitted to the ICU and 50% were
mechanically ventilated, compared to less than 50% of COVID-19 patients without stroke (p-value <
0.0001). Mortality was 37.5% in the COVID-19 and acute stroke group as compared to 8% in the COVID-19
without acute stroke group (p-value < 0.0001). The average inpatient length of stay, and the average ICU
length of stay, for patients with COVID-19 and acute stroke group are longer than for those without
COVID-19 (13.6 days vs. 7.9 days, p-value < 0.0088; 7.6 days vs. 1.6 days, p-value < 0.0001).
Only 0.8% of COVID-19 positive patients were identified to have acute ischemic stroke on ICD-10 principal
discharge diagnosis with independent MRI confirmation. COVID-19 patients with acute ischemic stroke
had a higher likelihood of facility discharge and increased inflammatory markers of D-dimer and white
blood cells.

CONCLUSION
COVID-19 patients with acute stroke had significantly worse morbidity and mortality outcomes than
COVID-19 patients without stroke. Acute ischemic stroke was infrequent in patients with COVID-19 (0.8%).
Biomarker validation of these elevated laboratory results may provide future treatment guidance for
COVID-19 patients with acute ischemic stroke.
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Effectiveness, Safety, and Tolerability of Repetitive
IV Dihydroergotamine in the Treatment of Refractory
Chronic Migraine – Avv Retrospective Review
Wang V, Kosman J, Yuan H, Hopkins M, Lauritsen C, Silberstein S

BACKGROUND
Dihydroergotamine (DHE), an ergot alkaloid, is an effective acute treatment for migraine, approved since
1945. Given its vasoconstrictive property, DHE use is contraindicated in patients with significant cardiovascular diseases. To date, few studies have characterized the safety and tolerability of DHE in populations
with elevated cardiovascular risk factors.

OBJECTIVES
To assess the safety, efficacy, and tolerability of repetitive intravenous (IV) DHE in our inpatients with
cardiovascular risk factors.

METHODS
A single-center, retrospective chart review was conducted at the Jefferson Headache Center (JHC)
inpatient unit for refractory chronic migraine patients treated with our IV DHE protocol between January
1, 2019 and October 15, 2019. We evaluated and compared key effectiveness and safety outcomes based
on patient atherosclerotic cardiovascular disease (ASCVD) 10-year risk scores into low (< 5%) or elevated
risk categories (≥ 5%).

RESULT
Among 227 patients (female 81.6%, age 53±15) with calculable ASCVD scores who received IV DHE, there
was a significant reduction in pain intensity from admission to discharge (4.5±2.8, p<0.001), with a
significantly higher reduction in patients with low compared to elevated ASCVD risk scores (4.7 vs. 3.9,
p=0.038). Patients with low ASCVD risk had higher initial (0.43 vs 0.38mg, p=0.010) and final doses of
DHE (0.84 vs 0.70mg, p<0.001). There were no clinically significant EKG abnormalities in either group. In
addition, there were no clinically significant cardiovascular events between groups. Except for a higher
rate of nausea in the low ASCVD group (31.9 vs 14.1%, p=0.006), there were no differences in patient-reported adverse events..

CONCLUSION
In this real-world study, patients receiving IV DHE by the JHC inpatient headache protocol had significantly
reduced pain severity at discharge. No clinically significant cardiac or EKG abnormalities were detected in
patients with elevated (or low) ASCVD risk. This suggests that repetitive IV DHE as part of the JHC inpatient
headache protocol is safe in patients with refractory chronic migraine.
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